HDHakan Doğruel

Hakan Doğruel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hakan Doğruel has a total of 121 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Genetic spectrum and genotype–phenotype associations in Paget's disease of bone: A nationwide multicenter study from Türkiye

    by Dilek Gogas Yavuz, Hazal Şalva, Pınar Ata, Ebru Arslan, Onur Hanoğlu, Mahsan Azimi, Zeliha Hekimsoy, Hakan Doğruel, Ramazan Sarı, Feyza Yener Öztürk, et al.

  • Open Access

    Real-World Comparison of Short-Term Adverse Events, Treatment Persistence, and Efficacy of Semaglutide and Tirzepatide: A Nationwide Multicenter Study

    by Sema Hepşen, Cem Haymana, Gizem Ertepe Küçükgöde, Büşra Özcan, Burak Özbaş, Arzu Or Koca, Berna İmge Aydoğan, Çiğdem Tura Bahadır, Emre Durcan, Volkan Yumuk, et al.

    Background: Real-world data directly comparing the safety, tolerability, and effectiveness of semaglutide and tirzepatide in patients with obesity remain limited. This nationwide multicenter observational study compared short-term adverse events, treatment discontinuation, body weight loss (BWL), and metabolic outcomes between the two treatments. Methods: This study included 2,549 patients with obesity treated with semaglutide (n=1,434) or tirzepatide (n=1,115). Adverse events, including time to onset, dose at occurrence, and related discontinuation, were evaluated. Changes in BWL and metabolic parameters up to 6 months were assessed. Subgroup analyses were performed in patients with and without type 2 diabetes mellitus (T2DM). Results: At least one adverse event occurred in 50.9% in the semaglutide group and 51.0% in the tirzepatide group (p=0.524), with gastrointestinal events the most frequently reported. Overall adverse event rates were comparable between groups; however, musculoskeletal and allergic reactions were more common in the tirzepatide group. The onset of gastrointestinal, neuropsychiatric, musculoskeletal symptoms, and hypoglycemia occurred earlier in the tirzepatide group. Discontinuation due to adverse events was similar between groups, except for pancreatic events, which were more frequent in the semaglutide group (p=0.006). Tirzepatide was associated with greater early BWL at all time points. At 6 months, median percentage BWL was 12.6% with semaglutide and 14.4% with tirzepatide. HbA1c reductions were comparable between groups in patients with T2DM. Conclusion: In real-world clinical practice, semaglutide and tirzepatide show similar short-term tolerability and treatment persistence, although tirzepatide is associated with a higher incidence of musculoskeletal and allergic reactions and greater early BWL.


  • Open Access

    Evolution of thyroid fine-needle aspiration biopsy performance over 15 years: implications for risk stratification in clinical practice

    by Hakan Doğruel, Elif Nur Karaoğlu, Nusret Yılmaz, Mustafa Aydemir, Hasan Çalış, Cumhur Arıcı, Güzide Ayşe Ocak, İnAnç Elif Gürer, Ramazan Sarı

    Objective: We aimed to evaluate temporal changes in the diagnostic performance of thyroid fine-needle aspiration biopsy (FNAB) over a 15-year period in a single-center, surgically confirmed cohort. Subjects and methods: We retrospectively analyzed thyroid FNABs performed between 2009 and 2023, dividing the data into two intervals (Group 1: 2009–2014; Group 2: 2015–2023). All specimens were interpreted by the same two experienced cytopathologists. Sensitivity, specificity, and Youden’s J were calculated at four diagnostic thresholds (≥AUS/FLUS, ≥FN/SFN, ≥SM, and malignant only), [...] ABSTRACT Objective: We aimed to evaluate temporal changes in the diagnostic performance of thyroid fine-needle aspiration biopsy (FNAB) over a 15-year period in a single-center, surgically confirmed cohort. Subjects and methods: We retrospectively analyzed thyroid FNABs performed between 2009 and 2023, dividing the data into two intervals (Group 1: 2009–2014; Group 2: 2015–2023). All specimens were interpreted by the same two experienced cytopathologists. Sensitivity, specificity, and Youden’s J were calculated at four diagnostic thresholds (≥AUS/FLUS, ≥FN/SFN, ≥SM, and malignant only),

  • Open Access

    Graves Orbitopatisi Tedavisinde Farklı İntravenöz Glukokortikoid Protokollerinin Karşılaştırılması: Tek Merkez Deneyimi

    by Hakan Doğruel, Olgar Öcal, Mustafa Aydemir, Nusret Yılmaz, Mine Genç Özay, Hatice Deniz İlHan, Ramazan Sarı

    ÖZ Amaç: Graves orbitopatisi (GO) sebebi ile intravenöz (IV) glukokortikoid tedavisi alan hastaların klinik verilerini değerlendirmek ve kullanılan tedavi protokollerini karşılaştırmak. Gereç ve Yöntemler: Merkezimizde GO sebebi ile sistemik glukokortikoid tedavisi alan hastaların klinik ve laboratuvar verileri retrospektif olarak incelendi. Rejim A (15 mg/kg metilprednizolon 2 hafta ara ile gün aşırı 2 doz şeklinde 4 siklus, sonrasında aynı sıklıkta 7,5 mg/kg metilprednizolon 4 siklus) alanlarla grup 1, rejim B (6 hafta boyunca haftada 1 gün 500 mg metilprenizolonu takiben 6 hafta boyunca haftada 1 gün 250 mg metilprednizolon) alanlarla ise grup 2 oluşturuldu. Grup 1 ve grup 2 verileri birbiri ile karşılaştırıldı. Bulgular: Çalışmaya; 11’i grup 1’de, 25’i ise grup 2’de olmak üzere toplam 36 hasta alındı. Hastaların yaş ortalaması grup 1’de grup 2’ye oranla daha yüksekti (Sırası ile 56±12,9 ve 46,8±10,2, p=0,02). Cinsiyet dağılımı ve sigara içen hasta sıklığı yönünden ise gruplar arasında fark saptanmadı. Ek otoimmun hastalık öyküsü tüm hastaların %20’sinde vardı. GO’nun tüm hastaların %88,9’unda hastalığın doğal seyrinde, %8,3’ünde radyoaktif iyot tedavisi sonrası, %2,8’inde ise tiroid cerrahisi sonrası geliştiği saptandı. Klinik aktivite skorunun her iki grupta tedavi ile benzer oranda azaldığı saptandı. The European Group on Graves’ Orbitopathy (EUGOGO) ciddiyet sınıfı, diplopi, yumuşak doku tutulumu, kapak retraksiyonu, propitozis ve kornea hasarı yönünden yapılan değerlendirmede tedavi ile istatistiksel anlamlılığa ulaşan yarar sağlanmadığı saptandı. Sonuç : Sistemik intravenöz glukokortikoid tedavisi, immünsüpressif tedavi endikasyonu konulan GO hastalarında hastalık aktivitesini baskılama yönünden etkili bir tedavi seçeneğidir. Her iki grupta KAS düşüşü benzer saptanmıştır. Daha düşük kümülatif steroid dozu kullanılarak benzer etki elde edilmesi rejim B kullanımını destekler niteliktedir.

  • An extremely rare case of hypoglycemia with a novel mutation and review of the literature: fructose-1,6 bisphosphatase deficiency in an adult man

    by Hakan Doğruel, Mustafa Aydemir, Nusret Yılmaz, Ramazan Sarı

    Hypoglycemia is an uncommon clinical problem among non-diabetic patients. It requires systematic evaluation to determine the etiology. It may be related to critical illness, hepatic insufficiency, renal insufficiency, cardiac insufficiency, drugs, alcohol, cortisol insufficiency, growth hormone insufficiency, insulinoma, gastric bypass surgery, and paraneoplastic (insulin-like growth factor-2–related) immune-mediated or inherited metabolic disorders. We aimed to summarize the literature and present a case who suffered from hypoglycemia throughout his life and was diagnosed with fructose-1, 6 bisphosphatase deficiency in adulthood to attract attention to the rare causes of hypoglycemia in adulthood.


  • Open Access

    The association of vitamin D status with inflammatory parameters and proteinuria in patients with stage 3-5 chronic kidney disease who are not on renal replacement therapy

    by Hakan Doğruel, Feyza Bora, Fettah Fevzi Ersoy

    Amaç: Kronik böbrek hastalığı (KBH) ve proteinürisi olanlarda artmış oksidatif stres ve inflamasyonun kardiyovasküler morbidite ve mortalite ile ilişkili olduğu gösterilmiştir. Vitamin D’nin (VD) organizmada birçok rolünün olduğu son yıllarda VD reseptörünün çok sayıda dokuda gösterilmesiyle anlaşılmıştır. Bu çalışmada KBH olan bireylerde VD düzeyinin, inflamatuvar parametreler ve proteinüri ile ilişkisini değerlendirmeyi amaçladık. Gereç-Yöntem: Çalışmaya nefroloji polikliniğinde takip edilen ve henüz renal replasman tedavisi almamış, evre 3-5 KBH hastalar arasından dahil etme kriterlerini karşılayan 314 hasta alındı. Katılımcıların verileri retrospektif ve kesitsel olarak incelendi. Demografik özellikleri, kreatinin, tahmini glomerüler filtrasyon hızı (t GFH), serum 25(OH)D3, kalsiyum, albümin, fosfor, parathormon (PTH), spot idrarda protein/kreatinin oranı, nötrofil, lenfosit, platelet, nötrofil/lenfosit oranı (NLO) ve platelet/lenfosit oranı (PLO) kaydedildi. Serum 25(OH)D3 düzeyine göre; VD eksikliği olanlar, (29 ng/ml) olmak üzere 3 grup oluşturuldu. Gruplar, inflamatuvar parametreler ve proteinüri düzeyi yönünden karşılaştırıldı. Analizler SPSS 23.0 programı ile yapıldı. Bulgular: VD grupları arasında inflamatuvar parametreler (CRP, NLO ve PLO) açısından fark saptanmadı. Spot idrarda protein/kreatinin oranı VD eksikliği olanlarda, hem VD yetersizliği olanlardan (p:0, 007) hem de VD düzeyi normal olanlardan (p: 0,001) daha yüksekti. Ayrıca yapılan korelasyon analizinde VD düzeyi ile proteinüri arasında negative korelasyon saptandı (r: -267, p: <0,01). Nefrotik düzeyin altında proteinürisi olan bireylerde de VD düzeyi ve proteinüri ilişkisinin korunduğu saptandı (p: 0,018). Sonuç: Proteinüri düzeyinin, VD düzeyi ile negatif korelasyon gösterdiği ve VD eksikliği olanlarda daha yüksek değerlere ulaştığı görüldü. Bu noktada renal ve kardiyovasküler açıdan önemli bir faktör olan proteinürinin azaltılması noktasında VD’nin rolü gündeme gelebilir. Objective: It has been demonstrated that increased oxidative stress and inflammation are associated with increased cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD) and proteinuria. In recent years, it has been understood that vitamin D (VD) has many roles, with the demonstration of the VD receptor in many tissues. In this study, we aimed to evaluate the association of VD level with inflammatory parameters and proteinuria in individuals with CKD. Method: The study included 314 patients who were followed up in the nephrology outpatient clinic with the diagnosis of CKD, had not received renal replacement therapy yet and met the inclusion criteria. The data of the participants were analyzed retrospectively and cross-sectionally. Demographic characteristics, creatinine, estimated glomerular filtration rate, serum 25(OH)D3, calcium, albumin, phosphorus, parathormone (PTH), spot urine protein/creatinine ratio, neutrophil, lymphocyte, platelet, neutrophil/lymphocyte ratio (NLR) and platelet /lymphocyte ratio (PLR) were recorded. According to serum 25(OH)D3 level; Three groups were formed those with VD deficiency (29 ng/ml). The groups were compared in terms of inflammatory parameters and proteinuria levels. Analyzes were performed by using the SPSS 23.0 program. Results: There was no difference between the VD groups in terms of inflammatory parameters (CRP, NLR, and PLR). The protein/creatinine ratio in spot urine was higher in patients with VD deficiency than both those with VD insufficiency (p:0.007) and those with normal VD levels (p:0.001). In addition, a negative correlation was found between VD level and proteinuria (r: -267, p: <0.01). It was found that the association between VD level and proteinuria was preserved in individuals with proteinuria below the nephrotic level (p: 0.018). Conclusion: It was observed that the proteinuria level was negatively correlated with the VD level and reached higher values in those with VD deficiency. At this point, the role of VD in reducing proteinuria, which is an important factor in renal and cardiovascular terms, may become a current issue.

  • Comparative evaluation of clinical outcomes of dapagliflozin and empagliflozin in type-2 diabetes mellitus

    by Hakan Doğruel, Hatice Tülüce Atlım, Mustafa Aydemir, Nusret Yılmaz, Ramazan Sarı

    Background Sodium-glucose transporter 2 (SGLT-2) inhibitors provide additional benefits besides glycemic control. Aim This study aims to compare the clinical outcomes of dapagliflozin and empagliflozin. Methods This retrospective study evaluated data retrieved from medical records of patients who were under follow-up with the diagnosis of type 2 diabetes mellitus (T2DM) and were started on dapagliflozin or empagliflozin treatment between January 1, 2017, and June 1, 2020. Demographic features, comorbidities, clinical features, duration of diabetes, baseline, and follow-up laboratory test results were recorded. The significance level was set at p < 0.05. Results This study comprised 342 patients who are on the treatment with dapagliflozin (n = 228) or empagliflozin (n = 114). The glycosylated hemoglobin a1c (HBA1C) level was significantly decreased in both the dapagliflozin (8.18–7.59, p < 0.001) and empagliflozin (8.35–7.58, p < 0.001) groups. The urine albumin-to-creatinine ratio (ACR) was also decreased in both groups. A decrease in urine ACR was observed independent of using a renin–angiotensin–aldosterone system (RAAS) blocker both in the whole group and in patients with diabetic nephropathy. The time to addition of a new anti-diabetic agent to the treatment was shorter in the dapagliflozin group (14.4 months vs 17.7 months, p = 0.041, respectively). Conclusion Dapagliflozin and empagliflozin are the drugs to choose for renoprotection in diabetics independent of the use of a RAAS blocker. Even the time to addition of a new anti-diabetic agent is longer in the empagliflozin group, head-to-head comparative trials are needed to asess the potential differences in this regard.